Fig. 3From: Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancerPatient reported QOL scores following treatment. AUASS (a) and IIEF (b) scores at baseline, on treatment, and 3, 6, 12, 18, 24, and 36 months post-treatment. The number of responses obtained at each time point is indicatedBack to article page